BIOCAD does its sums for growth
Russian biotech company BIOCAD plans to leverage competitive advantages to take 5% of the European medicines market
List view / Grid view
Russian biotech company BIOCAD plans to leverage competitive advantages to take 5% of the European medicines market
Phase 3 trials of Gilead’s fixed-dose (BIC/FTC/TAF) combination for HIV show high tolerability and low resistance
Treating people who start HIV treatment late with a package of low-cost drugs to prevent serious infections saves three lives for ...
Gilead has submitted a new drug application to the US FDA for treatments of HIV.
6 June 2017 | By Niamh Marriott, Junior Editor
Regulatory submissions to the EMA and FDA for a single-tablet, two-drug regimen of dolutegravir & rilpivirine for the maintenance treatment of HIV...
15 May 2017 | By Niamh Marriott, Junior Editor
A new study describes an ambitious but feasible path toward what may have seemed unachievable just a decade ago: an end to the AIDS epidemic in the US...
12 May 2017 | By Niamh Marriott, Junior Editor
From diagnosis of HIV to successful viral suppression: this new ECDC report summarises key findings concerning and the Continuum of HIV Care in Europe...
4 May 2017 | By Niamh Marriott, Junior Editor
Abivax’s lead therapeutic candidate ABX464 demonstrated the first reduction in HIV reservoirs ever observed in chronically infected HIV patients...
20 March 2017 | By Niamh Marriott, Junior Editor
Research published by BioMed Central’s open access journal AIDS Research and Therapy has investigated the use of lubricants...
15 March 2017 | By Mike Elliott, Vice President, Medical Affairs, Gilead Sciences
We caught up with Gilead’s Mike Elliott to find out the latest in HIV medication and whether a cure is finally within our reach…
1 December 2016 | By Niamh Louise Marriott, Digital Editor
Embarrassing Bodies' Dr Christian Jessen talks debunking the stigma surround this pandemic disease and explains why it's OK if we don't find a cure...
23 November 2016 | By Niamh Louise Marriott, Digital Content Producer
The two studies, FLAIR and ATLAS, will examine the safety and efficacy of monthly dosing with the two-drug, injectable regimen in both treatment-naïve...
24 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The cobas MPX assay enables donor screening laboratories to apply the most advanced PCR-based diagnostic technology to the surveillance of donated blood...
16 August 2016 | By ViiV Healthcare
ViiV Healthcare is undertaking two identical studies as part of a global phase III programme comparing a two-drug regimen of dolutegravir plus lamivudine, with a three-drug regimen of dolutegravir (Tivicay), plus the fixed-dose tablet tenofovir/emtricitabine (Truvada), to support regulatory filings as a treatment for HIV, for adults who have had…
19 July 2016 | By Victoria White, Digital Content Producer
Triumeq demonstrated superior efficacy compared with ATV/r plus TDF/FTC in 495 treatment-naïve women living with HIV...